RxDoctor Payments Data

Paulina Kluchka

Primary Care · Libertyville, ILNPI 1487439907

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 207 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,276, 3.9 times the $585 reported in 2023. Among primary care clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,355in general payments, 2019–2025

Across 207 payments — averaging $21.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$669
  • AbbVie$541
  • AstraZeneca$496
  • Axsome Therapeutics, Inc.$467
  • Lilly USA, LLC$394
  • Pfizer$306
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$4,355100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,355 in reported general payments places this provider in the 90th percentile of 150 primary care providers in Illinois.

See all primary care providers in Illinois

Medicare billing

Part B allowed, 2024
$15,894
Medicare patients
74
Services billed
235

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
WegovySemaglutide11$24,744
MounjaroTirzepatide18$20,943
Rosuvastatin Calcium51$498
Metoprolol Succinate16$439
Levothyroxine Sodium32$274
Valsartan11$246
Atorvastatin Calcium27$242
Losartan Potassium23$205
Simvastatin14$202
Lisinopril17$81
Hydrochlorothiazide16$54
Metformin Hcl15$42

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskWegovy$669$24,74411 claims
Lilly USA, LLCMounjaro$394$20,94318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 150 primary care providers in Illinois.

Other primary care in Libertyville

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →